Phase 2 DLBCL Clinical Trials
52 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 52 trials
Recruiting
Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B Cell LymphomaNHLNon-Hodgkin's Lymphoma+1 more
National Cancer Institute (NCI)132 enrolled1 locationNCT04002947
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)
Memorial Sloan Kettering Cancer Center42 enrolled8 locationsNCT06765317
Recruiting
Phase 2
CAR-T Followed by Bispecific Antibodies
DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine23 enrolled2 locationsNCT04889716
Recruiting
Phase 2
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University35 enrolled1 locationNCT07608978
Recruiting
Phase 2
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting
Phase 1Phase 2
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
CLLDLBCLMCL+3 more
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07259070
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled2 locationsNCT07249905
Recruiting
Phase 2
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Diffuse Large B-Cell Lymphoma (DLBCL)
University Health Network, Toronto40 enrolled3 locationsNCT06050694
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 2
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Diffuse Large B-Cell Lymphoma (DLBCL)
The First Affiliated Hospital of Soochow University35 enrolled1 locationNCT07499271
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 2
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD50 enrolled1 locationNCT07493148
Recruiting
Phase 2
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 1Phase 2
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 2
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
DLBCL
University of Rochester40 enrolled1 locationNCT03758989
Recruiting
Phase 2
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Diffuse Large B-Cell Lymphoma (DLBCL)
Tianjin Medical University Cancer Institute and Hospital58 enrolled1 locationNCT07397832
Recruiting
Phase 2
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Diffuse Large B Cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma
Virginia Commonwealth University21 enrolled1 locationNCT06846463